1.
Fetal Pediatr Pathol
; 41(5): 800-806, 2022 Oct.
Article
in English
| MEDLINE
| ID: mdl-34281475
ABSTRACT
BACKGROUND: Sirolimus constitutes a safe and effective treatment for cardiac manifestations of tuberous sclerosis complex (TSC) in children but only four cases describing prenatal treatment of rhabdomyomas with mTOR inhibitors have been published. CASE: In this case, sirolimus was initiated at 26 weeks´ gestation in a pregnant woman with TSC with a fetus with a large rabdomyoma conditioning severe arrythmia. There was a significant reduction in the tumor size with ongoing treatment and a partial reversion of the arrythmia. CONCLUSION: m-TOR inhibitors can be considered for severe cases of fetal rhabdomyomas with poor prognosis given its potencial benefits.
Subject(s)
Heart Neoplasms , Rhabdomyoma , Tuberous Sclerosis , Child , Female , Humans , Pregnancy , Arrhythmias, Cardiac , Fetus/pathology , Heart Neoplasms/drug therapy , Heart Neoplasms/pathology , Rhabdomyoma/drug therapy , Rhabdomyoma/pathology , Sirolimus/therapeutic use , Tuberous Sclerosis/complications , Tuberous Sclerosis/drug therapy
2.